We are doing this study to find the most effective, safe dose of an experimental drug called ivonescimab (the study drug) compared to pembrolizumb in adults with metastatic non-small cell lung cancer (NSCLC).

Non-small Cell Lung Cancer (NSCLC)

Adults ages 18+ who:

• Are diagnosed with metastatic (Stage IV) NSCLC
• Have high PD-L1 expression based tumor tissue testing
• Have not received any previous systemic treatment targeted toward metastatic NSCLC
• Have no known genomic alterations (e.g., EGFR, ALK, ROS1, and BRAF V600E) based on testing

For more information, contact the study team at annemarie.peters@duke.edu.

If you choose to join this study, you will get a random assignment (like a coin flip) to either:

• Get the study drug; OR
• Get the standard treatment, which is pembrolizumab

Regardless of your drug assignment, you will get and intravenous (IV) infusion every 3 weeks of either the study drug or pembrolizumab. The infusions will last for 1-2 hours each. You will get infusions for up to 2 years.